SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bae JM, Won YJ, Jung KW, Park JG. Annual report of the Korean central cancer registry program 2000. Cancer Res Treat. 2002; 34: 7783.
  • 2
    Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995; 311: 899909.
  • 3
    Bunn PAJr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998; 4: 10871100.
  • 4
    Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004; 22: 330353.
  • 5
    Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002; 20: 42854291.
  • 6
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 9298.
  • 7
    Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003; 21: 30163024.
  • 8
    Briasoulis E, Karavasilis V, Anastasopoulos D, et al. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol. 1999; 10: 701706.
  • 9
    Hainsworth JD, Burris HA,3rd, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998; 16: 21642168.
  • 10
    Gervais R, Ducolone A, Breton JL, et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2005; 16: 9096.
  • 11
    Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer. 2004; 91: 19962004.
  • 12
    Schuette W, Nagel S, Blankenburg T, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol. 2005; 23: 83898395.
  • 13
    Inoue A, Kunitoh H, Mori K, Nukiwa T, Fukuoka M, Saijo N. Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer. Lung Cancer. 2002; 38: 205209.
  • 14
    Koizumi T, Tsunoda T, Fujimoto K, et al. Phase I trial of weekly docetaxel combined with cisplatin in patients with non-small cell lung cancer. Lung Cancer. 2001; 34: 125131.
  • 15
    Sato K, Tsuchiya S, Minato K, et al. A phase I study of weekly docetaxel and cisplatin in advanced non-small cell lung cancer. Lung Cancer. 2001; 33: 6973.
  • 16
    Kaira K, Takise A, Minato K, et al. Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer. Anticancer Drugs. 2005; 16: 455460.
  • 17
    Niho S, Ohe Y, Kakinuma R, et al. Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer. Lung Cancer. 2002; 35: 209214.
  • 18
    Ohe Y, Niho S, Kakinuma R, et al. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol. 2004; 15: 4550.
  • 19
    Tsunoda T, Koizumi T, Hayasaka M, et al. Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2004; 54: 173177.
  • 20
    Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365376.
  • 21
    Yun YH, Park YS, Lee ES, et al. Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res. 2004; 13: 863868.
  • 22
    Camps C, Massuti B, Jimenez A, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol. 2006; 17: 467472.
  • 23
    Kvinnsland S. The leucocyte nadir, a predictor of chemotherapy efficacy? Br J Cancer. 1999; 80: 1681.
  • 24
    Di Maio M, Gridelli C, Gallo C, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol. 2005; 6: 669677.
  • 25
    Kubota K, Watanabe K, Kunitoh H, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol. 2004; 22: 254261.
  • 26
    Gridelli C, Perrone F, Palmeri S, et al. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: a phase III multicentre randomised trial. The “Gruppo Oncologico Centro-Sud-Isole” (G.O.C.S.I.). Ann Oncol. 1996; 7: 821826.
  • 27
    Luedke DW, Einhorn L, Omura GA, et al. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial. J Clin Oncol. 1990; 8: 886891.
  • 28
    Lilenbaum RC, Langenberg P, Dickersin K. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival. Cancer. 1998; 82: 116126.
  • 29
    Lilenbaum RC, Rubin M, Samuel J, et al. A phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status (PS) patients (pts) with advanced non-small cell lung cancer (NSCLC). [abstract]. Proc Am Soc Clin Oncol. 2004; 22. Abstract 7057.